Three different HLA-A2.1 monochains were engineered in which either the human or mouse ␤ 2-microglobulin ( ␤ 2m) is covalently linked to the NH 2 terminus of the heavy chain by a 15-amino acid long peptide: HHH, entirely human, HHD, with the mouse H-2D b ␣ 3, transmembrane, and cytoplasmic domains, and MHD, homologous to HHD but linked to the mouse ␤ 2m b . The cell surface expression and immunological capacities of the three monochains were compared with transfected cells, and the selected HHD construct was introduced by transgenesis in H-2D b Ϫ / Ϫ ␤ 2m Ϫ / Ϫ double knockout mice. Expression of this monochain restores a sizable peripheral CD8 ϩ T cell repertoire essentially educated on the transgenic human molecule. Consequently, infected HHD, H-2D b Ϫ / Ϫ ␤ 2m Ϫ / Ϫ mice generate only HLA-A2.1-restricted CD8 ϩ CTL responses against influenza A and vaccinia viruses. Interestingly, the CTL response to influenza A virus is mostly, if not exclusively, directed to the 58-66 matrix peptide which is the HLA-A2.1-restricted immunodominant epitope in humans. Such mice might constitute a versatile animal model for the study of HLA-A2.1-restricted CTL responses of vaccine interest.
T ransgenic mice expressing unmodified HLA class I molecules have been derived in many laboratories to provide a suitable animal model for the study of HLA class I-restricted CTL responses (1) . Despite a few reported successes (2-6), these attempts have been relatively disappointing; when virus infected or stimulated by other HLA class I alleles, these mice preferentially (most of the time exclusively) develop H-2-restricted CD8 ϩ CTL responses (7) (8) (9) (10) . Substitution of the HLA ␣ 3 by the homologous H-2 domain significantly improves the recognition and usage of some (A2.1, B27), however not all (i.e., B7.1, our unpublished observation), HLA class I molecules (11, 12) . Similarly, we and others have established that recognition and usage of transgenic HLA class I molecules by mouse CD8 ϩ T lymphocytes can be promoted when H-2-restricted responses are controlled. More importantly, under such circumstances, a diversified V ␤ and V ␣ TCR mouse repertoire is mobilized, suggesting a sufficient flexibility for an efficient usage of human class I molecules (13, 14) . However, the experimental artifices (cross-tolerance, serial stimulations in vitro with appropriate antigen presenting cells) selected to favor the HLA-restricted CTL responses in transgenic mice are not of convenient usage. Therefore, we have derived mice expressing only HLA class I molecules to force the mouse CD8 ϩ T cell repertoire, both at the thymic and peripheral levels, to make use of the transgenic HLA class I molecules. These mice are H-2D b and mouse ␤ 2 microglobulin ( ␤ 2m) 1 double knockouts and express ␤ 2m-HLA-A2.1 monochains.
We report in vitro transfection experiments that resulted in the selection of a human ␤ 2m-HLA-A2.1 ( ␣ 1 ␣ 2)-H-2D b ( ␣ 3 transmembrane cytoplasmic) (HHD) monochain construct to derive transgenic animals. These HHD transgenic, H-2D b Ϫ / Ϫ ␤ 2m Ϫ / Ϫ double knockout mice are almost devoid of H-2 class I molecules. Phenotypic and functional analyses of their peripheral CD8 ϩ T cell repertoire indicate that HHD monochains support thymic positive selection of CD8 ϩ CTL and activate virus-specific HLA-A2.1-restricted CTL in the periphery.
Materials and Methods
Plasmids. The 2.2-kb EcoRI-BglII fragment encompassing the promoter and the three first exons from the HLA-A2.1 gene (10) was subcloned in a modified BglII ϩ pBluescript (Stratagene, La Jolla, CA) and site mutagenized to introduce a PstI site at the HHD Transgenic H-2D b Ϫ / Ϫ ␤ 2m Ϫ / Ϫ Double Knockout Mice 3 Ј end of the first exon and a BamHI site at the 5 Ј end of the second exon (HLA-A2.1 PB plasmid). BamHI and MscI restriction sites were introduced at the 5 Ј and 3 Ј ends of human ␤ 2m and murine ␤ 2m b cDNA, respectively, corresponding to the mature form (without leader sequence) of the proteins. A three-partner ligation was performed between the 5 Ј PstI (T4 polymerase blunt ended), 3 Ј BamHI-digested HLA-A2.1 PB plasmid, the 5 Ј BamHI (Klenow blunt ended), 3 Ј MscI-digested human or murine ␤ 2m cDNA, and a pair of complementary synthetic oligonucleotides (Genset, Paris, France) coding for a (Gly 4 Ser) 3 linker with 5 Ј blunt and 3 Ј BamHI cohesive end. Final constructs were verified by double-stranded DNA sequencing (Sequenase version 2.0; United States Biochemical, Cleveland, OH). In the final recombinant plasmids, super-exon I codes for the HLA-A2.1 leader sequence, the human or mouse ␤ 2m, a 15 amino acid linker, and the ␣ 1 domain of HLA-A2.1. A 5.1-kb BglII-BamHI or a 2.3-kb BamHI fragment containing the fourth to eighth exons and the 3 Ј untranslated region of the HLA-A2.1 or H-2D b genes, respectively, was subsequently introduced in the BglII site of this construct. This provided the entirely human HHH, human ␤ 2m-HLA-A2.1 ( ␣ 1 ␣ 2) H-2D b ( ␣ 3 to COOH terminus) HHD, and mouse ␤ 2m b -HLA-A2.1 ( ␣ 1 ␣ 2) H-2D b ( ␣ 3 to COOH terminus) MHD coding plasmids.
A control construct was also created introducing the BamHI 3 Ј fragment of the H-2D b gene in the BglII site of the HLA-A2.1 gene (in wild-type configuration) providing a chimeric (HLA-A2.1 ␣ 1 ␣ 2, H-2D b ␣ 3, transmembrane and cytoplasmic) heavy chain.
Cells and Transfectants. RMA (transporter associated with antigen presentation [TAP] positive), RMA-S (TAP negative), EL4 ( ␤ 2m positive), and EL4 S3 Rob ( ␤ 2m negative) C57Bl/6 (H-2 b ) lymphoma cells were maintained in RPMI, 10% FCS. Cells (5 ϫ 10 7 ) in 500 l of PBS were electroporated with 50 g of plasmid constructs and 1 g of pMCS (15) linearized DNA at 250 V and either 1,500 (RMA, RMA-S) or 1,050 (EL4, EL4 S3 Rob) F using an Easyject gene pulser (Eurogentec, Seraing, Belgium). After 24 h, cells were transferred in selective medium containing 1 mg/ml G418 (GIBCO BRL, Paislay, U.K.) and cloned by limiting dilution. Neomycin-resistant clones expressing the monochains were identified by indirect immunofluorescence using unlabeled B9.12.1 (anti-HLA class I, F(ab) Ј 2) and goat anti-mouse Ig (F(ab) Ј 2) FITC-conjugated antibodies and analyzed by flow cytofluorometry with a FACScan  (Becton Dickinson, San Jose, CA).
Immunoprecipitations. Cells (5 ϫ 10 6 ) were washed in methionine-and cystein-free RPMI medium (ICN Biomedicals, Inc., Costa Mesa, CA) supplemented with 10% dialyzed FCS and incubated for 45 min at 37ЊC in 1 ml of the same medium before labeling for 15 min with 1 mCi of [ 35 S] methionine-cystein mix (Pro-mix; Amersham, Buckinghamshire, U.K.). Pelleted cells were lysed in PBS containing 1% BSA and 1% NP-40 (BDH Chemicals, Ltd., Poole, U.K.). Lysates were precleared (2 h, 4ЊC with protein A-Sepharose beads) and then incubated overnight at 4ЊC with 10 g of purified anti-HLA-A2.1 (BB7.2) mAb. After addition of protein A-Sepharose beads and further incubation for 2 h at 4ЊC, beads were washed four times with 60 mM Tris HCl, pH 7.4, 150 mM NaCl, 0.5% deoxycholic acid, 5 mM EDTA, 1% NP-40, 0.1% SDS. Proteins were eluted, denatured, and separated by SDS-PAGE on 12% gels. Dryed gels were exposed on a Phosphorimager screen (Molecular Dynamics, Sunnyvale, CA) and analyzed using Imagequant program (Molecular Dynamics).
Generation of CTL and Cytolytic Assays. HLA-A3 transgenic C57Bl/6 mice were injected intraperitoneally with 3 ϫ 10 7 HLA-A2.1 ϫ human ␤2m transgenic C57Bl/6 mouse splenocytes. 2 wk later, splenocytes (5 ϫ 10 7 ) from immunized mice were restimulated in vitro with 3 ϫ 10 7 irradiated (2,000 rads) HLA-A2.1 ϫ human ␤2m transgenic splenocytes for 5 d. Human recombinant IL-2 (Santa Cruz Biotechnology, Santa Cruz, CA) was added on day 3 of culture.
Influenza A-specific, HLA-A2.1-restricted HAM 42 CTL clone generated in HLA-A2.1 transgenic mice (8) , was provided by Dr. V. Engelhard and maintained in vitro by weekly restimulation with HLA-A2.1-positive JY human lymphoblastoid cells, pulsed with 10 Ϫ6 M of influenza A matrix 58-66 synthetic peptide GILGFVFTL.
HHD ϩ H-2D bϪ/Ϫ ␤2m Ϫ/Ϫ mice were intraperitoneally infected with either 1,000 hemagglutinin (HA) units (influenza A/PR/8/ 34, provided by Dr. J.-C. Manuguerra, Laboratoire de Genetiq Moleculair des Virus Respiratoir Institut Pasteur, Paris, France) or 10 7 PFU (vaccinia) viruses. 2-4 wk later, 2.5 ϫ 10 7 (influenza A) or 6 ϫ 10 7 (vaccinia) splenocytes were restimulated in vitro with 2.5 ϫ 10 7 (influenza A) or 3 ϫ 10 7 (vaccinia) irradiated (3,000 rads) syngeneic red blood cell-depleted splenocytes infected for 1 h with influenza A (10 HA unit for 10 6 cells) or vaccinia (10 PFU/cell) viruses.
Responder mice were individually tested in a standard cytolytic assay 5 d later. In brief, 10 6 cells, uninfected or infected (1,000 HA units of influenza A or 5 ϫ 10 7 PFU of vaccinia viruses) for 1.5 h in medium without FCS and further incubated for 2 h in medium containing 5% FCS, were subsequently labeled with 100 Ci of sodium [ 51 Cr]chromate for 1.5 h at 37ЊC and then washed three times. Cytolytic activity was determined in 4 h 51 Cr-release assays using V-bottom 96-well plates containing 5 ϫ Generation of H-2D bϪ/Ϫ Knockout Mice. A 10-kb HindIII fragment containing the whole H-2D b gene and a 1.9-kb PstI fragment encompassing the 3Ј part of the third exon, the fourth intron, and the 5Ј part of the fourth exon were cloned in pBluescript (Stratagene) vector. The H-2D b targeting construct was generated by inserting a 4-kb XbaI 5Ј fragment from the H-2D b gene and a 1.3-kb KpnI 3Ј fragment from the PstI subclone in the corresponding restriction sites of the pGNA vector polylinker (16) . CGR-8 embryonic stem cells were cultured as described (17) in the absence of feeder cells in medium supplemented with murine differentiation inhibiting factor and/or leukemia inhibiting factor. To isolate homologous recombinants, 10 8 cells were electroporated in 900 l of PBS with 150 g of SpeI-linearized plasmid DNA at 800 V and 3 F, using a Bio Rad Labs. (Hercules, CA) gene pulser and selected after 24 h in the presence of G418 (175 g/ml). 28 pools of 12 G418-resistant clones were screened by PCR, using a pGNA-specific 5Ј (CAGCAGAAACATACAAGCTGTC) and a H-2D b exon 5-specific 3Ј (AACGATCACCATGTAAGAGT-CAGT) pair of oligonucleotides, resulting in the amplification of the expected 1.6-kb fragment for 18 pools. The homologous recombination event, detected by hybridization of a 5.6-kb HindIII fragment with a 3Ј noncoding BamHI-HindIII probe, was confirmed in six colonies by Southern blot analysis. Two out of five clones injected into C57BL/6 blastocysts gave rise to germline transmission of the mutation. Germline chimeras were mated with C57Bl/6 females and pups were typed by Southern blot analysis of tail DNA. Heterozygous offspring were backcrossed to C57BL/6 animals and then intercrossed at the N2 generation to give rise to two independent H-2D bϪ/Ϫ homozygous strains. Inactivation of the H-2D b gene was confirmed by Southern blot analysis on tail DNA and immunofluorescence assay. (18) . Staining of 10 6 cells was performed in 100 l of PBS with 0.02% sodium azide for 30 min on ice. Purified mAb or F(ab)Ј2 were used at 10 g/ml and F(ab)Ј2 FITCconjugated goat anti-mouse IgG was used 1:100 diluted. A total of 25,000 1% paraformaldehyde-fixed cells per sample was subjected to one-or two-color analysis on FACScan  .
Generation of HHD Transgenic

Results
Design of HLA-A2.1 Monochains. Recombinant genes encoding HLA-A2.1 monochains were engineered, as illustrated in Fig. 1 , by introducing between the first and second exon of the genomic HLA-A2.1 gene a ␤2m cDNA (deprived of from the nucleotides corresponding to the leader sequence) and a pair of synthetic oligonucleotides encoding a 15 residue (Gly 4 Ser) 3 peptide linker, as already described (19, 20) . The first intron of the HLA-A2.1 gene was therefore deleted resulting in a chimeric exon 1 that codes for the leader sequence of HLA-A2.1, the ␤2m domain, the peptide linker, and the HLA-A2.1 ␣1 domain. Three different HLA-A2.1 monochains were engineered: HHH, fully human; HHD, containing the mouse H-2D b ␣3, transmembrane, and cytoplasmic domains; and MHD, homologous to HHD, with the mouse instead of the human ␤2m. All constructs, verified by sequencing, encode monochains in which the amino acid sequence of the leader, mature ␤2m, and ␣1 domains are totally conserved.
Expression in RMA Cells. By indirect immunofluorescence analysis of RMA lymphoma transfected cells (Fig. 2 A) , cell surface expression of HHH, HHD, and MHD monochains was compared to the cell surface expression of their heterodimeric counterparts. Despite selection of transfectants expressing similar amounts of monochain transcripts (as judged by semiquantitative PCR, data not shown) cell surface expression reaches the level of control cells only for HHH and HHD monochains. Surtransfection of MHDexpressing cells with the human ␤2m gene corrects the defect of cell surface expression of this monochain (data not shown), suggesting, in spite of their covalent linkage, poor interaction between the mouse ␤2m and the HLA-A2.1 ␣1 and ␣2 domains (21, 22) . Tested with a panel of nine HLA-A2.1-specific mAb (data not shown), the three monochains exhibited normal serological reactivities, indicating that the peptide linker does not markedly alter the overall threedimensional structure of the HLA-A2.1 molecule.
HLA-A2.1 monochains were exclusively detected as 60-kD proteins by immunoprecipitation using HLA-A2.1-specific BB7.2 mAb and PAGE analysis, suggesting that the fused molecules are not proteolytically separated after synthesis (Fig. 2 B) .
Finally, recognition by mouse CTL of the monochains was evaluated (Fig. 3 ). An influenza A matrix-specific, HLA-A2.1-restricted CTL clone (HAM 42; 14) was first tested on target cells pulsed with synthetic 58-66 influenza matrix pep- tides. This CTL clone killed HHH-, HHD-, and MHD-RMA monochain transfectants and RMA cells expressing heterodimeric HLA-A2.1 ϫ human ␤2m molecules with approximately the same efficiency (Fig. 3 A) . Expression by the MHD and HHD monochains of a mouse H-2D b ␣3 domain that should facilitate their interaction with mouse CD8 molecules did not result in more efficient lysis, under our experimental conditions, by HAM 42 clone. CD8-independent recognition of target cells has been observed for some CTL clones, possibly related to the expression by these clones of TCR of high affinity (23) . Therefore, to more precisely evaluate the impact of the mouse ␣3 domain on the recognition by mouse CTL of the HLA-A2.1 monochains, the same target cells were tested with polyclonally activated, HLA-A2.1-specific CTL, raised by immunization of C57BL/6 HLA-A3 transgenic mice with splenocytes of C57BL/6 HLA-A2.1 ϫ human ␤2m double transgenic mice. Such polyclonally activated CTL specifically lyse HLA-A2.1-positive human cell line (JY), HLA-A2.1 transfected P815(H-2 d ), and RMA(H-2 b ) murine cell lines (data not shown), as well as the three monochain transfectants. However, MHD and, more strikingly, HHD monochain transfectants were more efficiently recognized (Fig. 3 B) . Thus, as already documented for heterodimeric HLA-A2.1 molecules (12), recognition by mouse CTL of the HLA-A2.1 monochains is facilitated by the introduction of a mouse ␣3 domain. Altogether, these in vitro studies of transfected cells show that the three HLA-A2.1 monochains are cell-surface expressed, serologically not altered, bind exogenous peptides, and are recognized by CTL. This suggests that they have a three-dimensional structure similar to wild-type heterodimeric molecules. They further argue for the selection of HHD molecules that are efficiently cell-surface expressed and that interact with the mouse CD8 molecules.
Peptide-dependency of Cell Surface Expression. Monochain constructs were introduced in TAP-deficient RMA-S cells to test whether cell surface expression of HLA-A2.1 monochains would be promoted at 25ЊC and stabilized at 37ЊC by the fixation of exogenous peptides (24) . The results of these experiments are illustrated in Fig. 4 . Cultivating transfected RMA-S cells at 25ЊC resulted in enhanced cellsurface expression of HHH, HHD, and, to a lesser extent, MHD monochains, which were stabilized at 37ЊC by the fixation of the 58-66 influenza matrix peptide. Thus, HLA-A2.1 monochains exhibited the same peptide dependency for stabilization as their heterodimeric counterparts. Moreover, at the surface of RMA-S transfectants, a relatively high basal expression of HLA-A2.1 monochains was observed at 37ЊC in the absence of exogenous peptides, suggesting, as established for wild-type heterodimeric HLA-A2 (25, 26) , that HLA-A2.1 monochains in TAP-deficient cells bind a significant amount of hydrophobic leader peptides in the endoplasmic reticulum.
Monochain Expression in ␤2m-deficient Cells. ␤2m-deficient EL4 S3 Rob cells (27) were stably transfected with the monochain constructs to precisely evaluate the possibility that heavy chain-linked ␤2m could promote the reexpression of endogenous H-2 class I mouse heavy chains. To be in a situation analogous to that of ␤2m knockout mice, selected clones of transfectants were cultured in medium supplemented with FCS deprived of bovine ␤2m by extensive immunoadsorption on a bovine ␤2m-specific, CAB.297 mAb column (28) .
As illustrated in Fig. 5 , we found limited, however repeatedly observed, reexpression of H-2D b , a conclusion based on the fact that the B22.249.R.19 mAb reacts with the ␣1␣2 H-2D b domains. Since H-2D b molecules are furthermore susceptible to reach cell surfaces in the absence of endogenous ␤2m (29), we concluded that the production of HLA-A2.1 monochain transgenic mice should be associated with the destruction of both mouse ␤2m and H-2D b genes, by homologous recombination. Altogether, these in vitro studies using transfected cells show the integrity and the functional capacities of HLA-A2.1 monochains and led us to select the HHD construct for the production of the HLA-A2.1 monochain transgenics mice.
Expression of HHD Monochains in H-
A targeting construct in which exons 1, 2, and 3 of the H-2D b gene were replaced by a plasmid conferring resistance to G418, was electroporated in CGR-8 embryonic stem cells (30) , and homologous recombinants were identified at the clonal level by PCR and Southern blot analyses (Fig. 6) . After blastocyst injection and reimplantation, chimeric mice were obtained, which gave germline transmission of the targeted gene. H-2D bϪ/Ϫ homozygous animals were then produced. These animals show no profound quantitative and qualitative modifications of their CD8 ϩ T cell repertoire (data not shown, Perarnau et al., manuscript in preparation). These H-2D Ϫ/Ϫ mice were crossed with ␤2m Ϫ/Ϫ knockout mice (31) to derive H-2D bϪ/Ϫ ␤2m Ϫ/Ϫ double mutants. Since initial attempts to use these mice for transgenesis failed, C57BL/6 ϫ SJL were used as recipients. Transgenic animals identified by Southern blotting and serological analyses were crossed with H-2D bϪ/Ϫ ␤2m Ϫ/Ϫ knockout mice to derive HHD (heterozygous) H-2D bϪ/Ϫ ␤2m Ϫ/Ϫ experimental animals.
Weak (compared to endogenous H-2 class I molecules in normal mice), but significant, expression of the transgenic HHD molecules on unactivated peripheral T lymphocytes was documented by indirect immunofluorescence and FACS  analysis. Under similar conditions, no H-2K b and H-2D b molecules could be detected (Fig. 7 A) . This expression of HHD monochains partially restores the peripheral pool of CD8 ϩ T lymphocytes (5.5% of the T lymphocytes instead of 20-30% in normal mice). More importantly, testing the 10 available anti-V␤ mAb, it appeared, as illustrated in Fig.  7 B for V␤8, that these CD8 ϩ T lymphocytes exhibited a diversified TCR repertoire. By comparison with H-2D bϪ/Ϫ ␤2m Ϫ/Ϫ double knockout mice, which are almost com- pletely deprived of peripheral CD8 ϩ T lymphocytes, these results suggest that HHD monochains promote CD8 ϩ T cell positive education in the thymus.
CTL Responses of HHD H-2D bϪ / Ϫ ␤2m Ϫ / Ϫ Mice. HHD (heterozygous) H-2D bϪ/Ϫ ␤2m Ϫ/Ϫ animals were intraperitoneally infected with either vaccinia or influenza A viruses. 2-4 wk later, splenocytes were restimulated in vitro with virus-infected syngeneic irradiated splenocytes and tested 5 d later in a classical 51 Cr-release assay.
All animals tested (four out of four for each virus) have developed virus-specific, HHD-restricted CTL responses allowing the in vitro killing of virally infected HHD-transfected cells (Fig. 8) . No significant lysis was observed testing the effector cells on vaccinia-or influenza A-infected EL4 cells, indicating that the CTL generated were HLA-A2.1 restricted. Two additional points are worth mentioning. First, these CTL recognized uninfected HHD-transfected cells loaded with the 58-66 influenza A matrix peptide with the same efficiency as infected cells (Fig. 8 B) . Second, the CTL responses appeared strongly CD8 dependent, HHD-transfected cells (as well as their heterodimeric counterparts) being much more efficiently recognized than transfectants expressing a fully human molecule.
Discussion
Comparative analyses of the cell surface expression and CTL recognition of HHH, HHD, and MHD monochains led to the selection of the HHD construct for the development of HLA-A2.1 transgenic mice. Cell-surface expression of MHD monochains has constantly been found to be 5-10 times lower by FACS  analysis. We know, from pulsechase and endoglycosidase H digestion experiments, that MHD monochains egress slowly from the endoplasmic reticulum. HHH and HHD monochains, by contrast, leave this cellular compartment as rapidly as HLA-A2.1 ϫ human ␤2m heterodimers (data not shown). Better interaction with mouse CD8 molecules has been the key element for the selection of the HHD construct. A similar observation has already been made analyzing the CTL responses of transgenic mice expressing, as heterodimers, chimeric HLA-A2.1 ␣1␣2 ϫ H-2K b ␣3 transmembrane and cytoplasmic domain heavy chains (12) . Further improvement of this interaction might be expected, particularly for some other HLA class I alleles (i.e., HLA-B7), by site-directed mutagenesis of the ␣2 residues implicated in the CD8 binding site (32) . Alternatively, one might consider the possibility of introducing the human CD8 ␣ and ␤ chains by transgenesis.
Profound reduction in cell surface expression of H-2 class I molecules has been documented serologically after destruction of mouse ␤2m gene by homologous recombination (31, 33) . However, studying both ␤2m Ϫ tumor cells and ␤2m knockout mice, residual expression of H-2D b molecules has been described, indicating that a fraction of functionally conformed H-2D b heavy chains reaches the cell surface in the absence of ␤2m (34). Since it was observed ex vivo that HHD monochains promote, to a certain extent, H-2D b molecule cell surface export, it was of interest to have HHD molecules expressed in H-2D bϪ/Ϫ and ␤2m Ϫ/Ϫ double knockout mice. Nevertheless, such mice cannot be considered as completely devoid of cell surfaceexpressed classical H-2 class I molecules. In fetal thymic organ cultures from ␤2m Ϫ/Ϫ mice, H-2K b -restricted CTL can be positively selected in the presence of exogenously added ␤2m and peptides (35) . Additionally, H-2K b -specific CTL have been generated against ␤2m Ϫ cells, and H-2K b molecules can be detected at the surface of Con A-stimulated ␤2m Ϫ/Ϫ splenocytes, implying residual expression of ␤2m-free, H-2K b heavy chains (36) (37) (38) . This residual expression might account for the small percentage (0.4%) of CD8 ϩ T lymphocytes observed in H-2D b ␤2m double knockout mice (Fig. 7 B) . Even if it is generally assumed that ␤2m-free H-2K b heavy chains are expressed in lower Despite the residual expression of ␤2m-free H-2K b heavy chains and the relatively low expression level (for which we do not have definitive explanation) of HHD monochains by HHD (heterozygous) transgenic H-2D b ␤2m double knockout mice, the results reported indicate efficient usage of the HLA-A2.1 monochain both at the educational and effector levels by the mouse CD8 ϩ T lymphocytes. Expression of the monochain restores a sizable and diversified CD8 ϩ T cell repertoire, supporting the notion that no significant species bias prevents interactions between mouse TCR and HLA class I molecules (8, 13) . More complete restoration is anticipated once animals homozygous for the transgene will be isolated. It might be of importance to reach expression levels similar to those observed at the surface of human cells to study CTL responses against peptides that interact or are recognized with relatively low affinity. In the absence of both H-2D b and mouse ␤2m, it must be assumed that most peripheral CD8 ϩ T lymphocytes have been educated in the thymus on HHD monochains. This should facilitate the study of HLA class I-restricted responses compared to classical transgenic mice. One might hope that the information gained with these animals will be of human relevance. Two recently reported studies have indicated significant overlap between HLA-A2.1 transgenic mice and human CTL responses assaying a large panel of hepatitis C-and hepatitis B virus-derived T cell epitopes (39, 40) . The development in HHD animals of potent CTL responses against the immunodominant (in HLA-A2.1 individuals) matrix peptide, documented in this report, also support such possibility. We are planning to use these animals for a comparative study of the vaccine potential of the HLA-A2.1-restricted T cell epitopes already characterized in various human diseases and a comparison of the different vaccine strategies.
